Anti-TNF-alpha therapy in childhood pustular psoriasis.
Pereira
Teresa M
TM
Department of Dermatology and Venereology, Hospital de São Marcos, Braga, Portugal. dermato@hsmbraga.min-saude.pt
Vieira
Ana Paula
AP
Fernandes
José Carlos
JC
Antunes
Henedina
H
Basto
A Sousa
AS
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine; D000069285:Infliximab; D000068800:Etanercept